New relief in sight for dry mouth
February 1, 2001
New relief in sight for dry mouth
Watch and listen for signs and complaints of dry mouth in your patients. Dry mouth, or xerostomia, often goes untreated. More than 20% of Americans over age 50, about 15 million people, suffer xerostomia. Adding those under the age of 50 who suffer from xerostomia secondary to other medical conditions (such as diabetes or rheumatic diseases) or to drugs that induce xerostomia, the number increases to about 25 million.
Amarillo Biosciences Inc. plans to partner with Natrol Inc. to market the dietary supplement Salive to treat dry mouth. Salive is a pharmaceutical grade anhydrous crystallatine maltose and has been shown in clinical trials conducted by Amarillo Biosciences to "relieve complaints of dry mouth, enhance salivary function, and promote oral comfort." Salive will be marketed under the name Natrol Dry Mouth Relief.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content